Basit öğe kaydını göster

dc.contributor.authorPan, Qin
dc.contributor.authorFan, Jian-Gao
dc.contributor.authorYılmaz, Yusuf
dc.date.accessioned2023-08-31T10:31:09Z
dc.date.available2023-08-31T10:31:09Z
dc.date.issued2023en_US
dc.identifier.citationPan, Q., Fan, J. G., & Yilmaz, Y. (2023). Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease: An Incomplete Jigsaw Puzzle. Clinics in liver disease, 27(2), 317–332. https://doi.org/10.1016/j.cld.2023.01.013en_US
dc.identifier.issn1089-3261
dc.identifier.issn1557-8224
dc.identifier.urihttps://doi.org/10.1016/j.cld.2023.01.013
dc.identifier.urihttps://hdl.handle.net/11436/8206
dc.description.abstractMultiple pathways including insulin signaling, JNK1/2 of MAPK signaling, GLP-1R signaling, and NRs affect to maintain the homeostasis of lipid metabolism in normal liver. ERK1/2 and P38 of MAPK signaling pathway antagonistically regulate the auto-phagy of hepatocytes. Functional imbalance of these pathways leads to hepatic stea -tosis by triglyceride increase and autophagy inhibition, together with insulin resistance based on inhibitory phosphorylation of Irs. Liver steatosis provokes lipid peroxidation and ER stress, which result in hepatocyte injury and lobular inflammation. Besides, gut-derived microbial metabolite (eg, LPS) stimulates the TLR-dependent production of proinflammatory cytokines by macrophages. Both hepatic injury and cytokine-induced inflammatory response initiate the occurrence and development of NASH and related fibrosis. On ligand-based TGFBRs activation, HSCs obtain activated phenotype through the TGF-b signaling pathway. But the activation and population of HSCs can be inhibited by NRs and apoptosis, respectively. Abnormalities in these pathways disrupt the balance of ECM production and degradation of the liver, with an outcome of advanced fibrosis and cirrhosis. Despite the present knowledge of path-ogenic pathways, further researches are needed to highlight other ones underlying NAFLD effector cells and related pathological characteristics. Finishing this jigsaw puzzle could make access to the effective prevention and treatment of NAFLD, and keep patients free for NASH and related cirrhosis, and hepatocellular carcinoma.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNonalcoholic fatty liver diseaseen_US
dc.subjectNonalcoholic steatohepatitisen_US
dc.subjectLiver fibrosisen_US
dc.subjectSignaling pathwaysen_US
dc.subjectPathophysiologyen_US
dc.titlePathogenetic pathways in nonalcoholic fatty liver disease: An incomplete jigsaw puzzleen_US
dc.typearticleen_US
dc.contributor.departmentRTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorYılmaz, Yusuf
dc.identifier.doi10.1016/j.cld.2023.01.013en_US
dc.identifier.volume27en_US
dc.identifier.issue2en_US
dc.identifier.startpage317en_US
dc.identifier.endpage332en_US
dc.relation.journalClinics in Liver Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster